Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes.
Clear evidence guides doctors to switch to newer dual-action diabetes drugs when single GLP-1 therapy isn't enough, offering better blood sugar and weight control.
This evidence-based guideline using the GRADE framework synthesizes 8 RCTs and provides conditional recommendations for treatment intensification when GLP-1 receptor agonist monotherapy fails in type 2 diabetes. The panel favors switching to dual GIP/GLP-1 RA (tirzepatide-class) for glycemic and weight benefits, or FRC for glycemic-focused intensification, over simply switching to another GLP-1 RA.
What the study was
- Study design
- guideline
- Category
- cardiovascular_metabolic_glp1_sglt2
- Maturity
- Validated
- Journal
- Diabetes Res Clin Pract
Why it surfaced
Directly actionable clinical guideline from multinational panel covering the critical GLP-1 RA treatment sequencing question; immediately relevant to prescribers managing T2DM progression.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.